REVB
Revelation Biosciences Inc

4,469
Loading...
Loading...
News
all
press releases
Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug
The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.
Stocktwits·10h ago
News Placeholder
More News
News Placeholder
Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’
The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly.
Stocktwits·2mo ago
News Placeholder
FTSE 100 today: BoE rate decision looms; Vodafone names CFO; Whitbread reports
Investing.com -- British stocks opened lower on Thursday as investors looked ahead to the Bank of England’s rate decision, with markets broadly anticipating no change in interest rates at the meeting.
investing.com·3mo ago
News Placeholder
Frasers Group decides not to make offer for Revolution Beauty
Investing.com -- Frasers Group PLC (LON:FRAS) said on Thursday that it will not make an offer for a U.K.-based cosmetics and skincare retailer Revolution Beauty Group PLC (LON:REVB).
investing.com·3mo ago
News Placeholder
Frasers explores potential bid for Revolution Beauty, company confirms
investing.com·3mo ago
News Placeholder
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the...
Business Wire·7mo ago
News Placeholder
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the...
Business Wire·7mo ago
News Placeholder
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following...
Business Wire·8mo ago
News Placeholder
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of...
Business Wire·8mo ago
News Placeholder
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of...
Business Wire·8mo ago

Latest REVB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.